Sagimet Biosciences Inc.

By person

14 insiders · 24 transactions

12.0×

David Happel holds 12.0 times base salary in stock. $7.59M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what David Happel last reported holding, valued at $10.23, the price Series A Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Kemble George

Director

—

$4.34M (6) scheduled

−$4.34M

62,161

$636.08K

—

Happel David

President & CEO

$71.68K (3)

$1.16M (3)

−$1.09M

741,570

$7.59M

—

SEIDENBERG BETH C

Director

$750.00K (1)

—

+$750.00K

131,643

$1.35M

—

NEW ENTERPRISE ASSOCIATES 13 LP entity

10% owner

$480.00K (1)

$10.59K (1) scheduled

+$469.41K

3,000,275

$30.70M

+7,863%

Rozek Elizabeth

Chief Legal & Admin. Officer

—

$228.19K (4)

−$228.19K

224,414

$2.30M

—

Martins Eduardo Bruno

Chief Medical Officer

—

$121.03K (3)

−$121.03K

147,296

$1.51M

—

Chauche Thierry

Chief Financial Officer

—

$7.03K (1)

−$7.03K

59,688

$610.78K

—

NEA Partners 13, Limited Partnership entity

10% owner

—

3,000,275

$30.70M

−22.1%

KPCB PBD Associates, LLC entity

10% owner

—

1,899,475

$19.44M

+4,800%

Wu Jinzi Jason

Director

—

1,654,701

$16.93M

—

KERINS PATRICK J

10% owner

—

13,139

$134.45K

−98.5%

Parsey Merdad

Director

—

12,794

$130.92K

+47.4%

BASKETT FOREST

10% owner

—

11,300

$115.63K

−98.7%

SANDELL SCOTT D

10% owner

—

6,997

$71.60K

−99.2%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Sagimet Biosciences Inc.

By person

Individual transactions

What was left out